Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) and Pernix Therapeutics Holdings Inc. (NASDAQ:PTX), are influenced by contrast since they are both players in the Drug Manufacturers – Other. These factors are particularly influence the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation of the two firms.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals Inc.	40.74M	2.37	6.96M	-0.37	0.00
Pernix Therapeutics Holdings Inc.	N/A	0.00	N/A	-6.39	0.00

Demonstrates Cumberland Pharmaceuticals Inc. and Pernix Therapeutics Holdings Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 has Cumberland Pharmaceuticals Inc. and Pernix Therapeutics Holdings Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals Inc.	-17.08%	-7.6%	-5.1%
Pernix Therapeutics Holdings Inc.	0.00%	39.3%	-37.1%

Risk & Volatility

Cumberland Pharmaceuticals Inc.’s volatility measures that it’s 68.00% less volatile than S&P 500 due to its 0.32 beta. Pernix Therapeutics Holdings Inc.’s 0.7 beta is the reason why it is 30.00% less volatile than S&P 500.

Liquidity

Cumberland Pharmaceuticals Inc. has a Current Ratio of 4.1 and a Quick Ratio of 3.7. Competitively, Pernix Therapeutics Holdings Inc.’s Current Ratio is 1.1 and has 0.9 Quick Ratio. Cumberland Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Pernix Therapeutics Holdings Inc.

Insider & Institutional Ownership

Cumberland Pharmaceuticals Inc. and Pernix Therapeutics Holdings Inc. has shares held by institutional investors as follows: 32.4% and 15.4%. 36.9% are Cumberland Pharmaceuticals Inc.’s share held by insiders. On the other hand, insiders held about 0.1% of Pernix Therapeutics Holdings Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cumberland Pharmaceuticals Inc.	5.76%	8.09%	-8.84%	1.55%	-11.18%	-2.49%
Pernix Therapeutics Holdings Inc.	-35.31%	-56.87%	-56.87%	-81.01%	-92.28%	-50.71%

For the past year Cumberland Pharmaceuticals Inc.’s stock price has smaller decline than Pernix Therapeutics Holdings Inc.

Summary

Cumberland Pharmaceuticals Inc. beats Pernix Therapeutics Holdings Inc. on 6 of the 9 factors.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. It marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. The companyÂ’s product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. Its pre-approval products consist of Methotrexate injection for treating active rheumatoid, juvenile idiopathic, and psoriatic arthritis, as well as disabling psoriasis; and Totect injection for emergency oncology intervention, which helps to reverse the toxic effects of anthracycline chemotherapy in case of extravasation. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc, Nordic Group B.V., and Cumberland Emerging Technologies. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including neurology, pain, and psychiatry. The companyÂ’s products comprise Treximet, a fixed dose combination product indicated for the treatment of acute migraine; Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; and Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.